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Editorial
influenza a (H1N1) induced-myopathy: an 
important extrapulmonary complication
Miopatia induzida pelo vírus influenza A (H1N1): uma complicação extrapulmonar 
importante
Acary Souza Bulle Oliveira
Skeletal or voluntary muscles represent, in the aggregate, approximately 40 to 45% of the weight of our body. Regarding the prominence and visibility of muscle function, disorders of voluntary muscles would be immediately apparent. However, disorders of the muscular system, the myopathies, in some cases, may go undiagnosed for long 
periods. Even when myopathy is considered and a diagnosis is made, the assessment of its 
course and the clinical state of the affected individual may at times be difficult to delineate 
with precision, even when an inflammatory myopathy is considered1.
The inflammatory myopathies constitute a heterogeneous and large group of disorders, 
and they are the most common form of acquired myopathies. Some are focal and confined to 
one muscle or group of muscles, while others are widespread and involve the limb and axial 
muscles in a multifocal fashion. The inflammatory myopathies may be further classified etio-
logically into those that occur due to a known infective organism (viral, bacterial, fungal, or 
parasitic) and the idiopathic inflammatory myopathies, whose etiology is uncertain, but in 
many of which there is strong evidence that the muscle damage is immunogically mediated2.
Despite the existence of several types of virus inflammatory myopathy (virus myositis) in 
animals, the occurrence of this type of infective muscle inflammation in man has had an un-
certain status.
Influenza A and B viruses can cause widespread outbreaks of human disease with dev-
astating consequences. Influenza A viruses are classified based on the characteristics of two 
surface glycoproteins, hemagglutinin (H1 to H15), and neuraminidase (N1 to N9). All subtypes 
have been detected in viruses recovered from aquatic birds, which are the natural reservoir for 
influenza viruses. So far, only H1, H2, and H3 and N1 and N2 are associated with large-scale in-
fluenza outbreaks among humans. The WHO recently declared that the novel influenza H1N1 
virus was responsible for the 2009 flu pandemic. As the virus continues to spread globally and 
affect more individuals, more complications of this virus infection are being recognized.
In 1896, Leichtenstern first described the association as ‘muscular neuralgias’ affecting the 
back, thighs, and calves of patients3. Influenza-associated myopathy has been a well-known 
phenomenon, mainly in pediatric patients, but it has been rarely reported in adults. Most cas-
es are described during large influenza epidemics. Isolated cases and small clusters of influ-
enza A (H1N1)-induced myocarditis, alone or in conjunction with pericarditis or rhabdomy-
olysis, have been reported. A severe necrotizing myopathy with myoglobinuria has rarely been 
reported in influenza4-8. 
Although, in a recent prospective cohort study of 152 patients in England, measurement 
of cardiac troponins I and T to detect myocardial injury was used, none of the 12% of pa-
tients with elevated creatine kinase levels had evidence of cardiac involvement, suggesting 
that rhabdomyolysis is more common than myocarditis9. 
The pathogenesis of this influenza A form of myopathy is uncertain. Direct invasion of the 
muscle by the virus has been postulated, and the susceptibility of human muscle to the virus 
was demonstrated in tissue culture10. However, convincing evidence of viral invasion in vivo 
remains to be presented. Skeletal-muscle biopsies generally do not reveal direct viral infection. 
In patients with severe myalgia in the calves and with high creatine kinase (CK), degenerative 
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changes of a non-specific type were found in biopsy prepara-
tions. Pathological signs range from non-specific degenera-
tive changes and muscle cell vacuolization to patchy or ex-
tensive muscle necrosis. In rare patients, extensive muscle 
necrosis and infiltration of neutrophylic leukocytes, and plas-
ma cells in the endomisium have been demonstrated11. 
In this issue, a paper is presented, demonstrating abnor-
malities findings in skeletal muscle of ten critical ill patients 
(within 20 to 57 of age) with influenza A (H1N1) virus infec-
tion, the highest series in the literature, containing important 
clinical considerations about interaction between virus and 
muscle12. 
The skeletal-muscle biopsy was performed due to the 
high CK levels found (3,744,4±5,544,14 U/L). Traditionally, 
muscle enzymes have been used as indicators of disease ac-
tivity. Although elevated serum CK reflects muscle injury 
and is frequent on those with acute myositis, muscle necro-
sis was detected only in four patients. The main hallmarks 
of inflammatory myopathy, including inflammatory cells and 
perifascicular atrophy, or direct viral infection, were not dem-
onstrated in this series. Pathological signs ranged from non-
specific degenerative changes and alterations suggestive of 
metabolic dysfunction, which could be related to influenza 
A (H1N1) virus, toxic myopathy (oseltamivir), or poor clinical 
condition (critical illness). 
Oseltamivir is the pro-drug of Ro64-0802 (GS4071), a 
potent and selective inhibitor of influenza A and B virus 
neuraminidases, it has been used to treat patients with influ-
enza A infection. Antiviral drugs have been documented to 
shorten the course of the illness by only one or two days. One 
study on oseltamivir found that treatment may reduce some 
complications, but no studies have shown that treatment re-
duces fatal outcomes. Its administration did not significantly 
affect the distribution of convalescent serum antibody titres 
compared to placebo in any of the studies, suggesting that it 
does not impair the ability of the host to mount an immune 
response to the influenza virus. As previous trials in healthy 
subjects and in patients, the present studies showed oselta-
mivir to be well-tolerated. Mild-to-moderate, transient gas-
trointestinal adverse events were observed in some oseltami-
vir recipients. No muscle alterations have been described13. 
The term critical illness has been widely used to describe 
the condition of a patient with illness that is severe enough 
to be considered at risk of death or related to sepsis and 
multiple organ failure. Critical illness myopathy may be de-
veloped in patients treated in an intensive care unit (ICU), 
usually with respiratory support, for periods longer than ten 
days. The clinical picture is that of severe flaccid weakness of 
voluntary limb and neck muscles with paralysis of respirato-
ry muscles (mainly the diaphragm), leading to difficulties in 
weaning patients off the respirator. The serum CK is usually 
elevated but not to extreme levels, and some patients have 
normal levels. Electromyography (EMG) findings are het-
erogeneous: a mix of myopathic potentials and neurogenic 
features can be found. Muscle biopsy may show either non-
specific changes, such as atrophy of both fiber types, angu-
lated fibers, and fiber size variation, or myofiber necrosis and 
apoptotic changes, but the unique feature found in up to 80% 
of critical illness myopathy patients is selective loss of thick 
(myosin) filaments with preservation of Z-bands on elec-
tron microscopy14. This process has been related to excessive 
breakdown of muscle proteins, i.e., it represents a catabolic 
myopathy15. 
The study of Lorenzoni et al.12 that shows the presence of 
very high CK and muscle findings not characteristic of criti-
cal illness myopathy reinforces the association between the 
skeletal muscle-biopsy alterations described and influenza A 
(H1N1) infection. The mechanisms of viral pathogenesis are 
most likely complex. In addition to direct viral replication in 
epithelial cells, pro-inflammatory cytokine release and ab-
normalities in the interferon system may contribute to the 
morbidity and mortality. Death has been attributable to mul-
tisystem disease, including tracheobronchitis, pneumonia, 
myopericarditis, acute renal failure, disseminated intravas-
cular coagulation, hepatic centrilobular necrosis, and severe 
rhabdomyolysis with myoglobinuria13. 
Severe rhabdomyolysis could be one of the most impor-
tant causes of death in such presented patients.
The spectrum of influenza-induced myopathy, the cellu-
lar mechanism of tissue injury, and the effect of involvement 
of other tissues on mortality among, otherwise healthy peo-
ple, require further elucidation.
Considering one reported case of a child with fatal rhab-
domyolysis associated with influenza B infection and mus-
cle biopsy, which shows a clinically unsuspected carnitine 
palmitoyl transferase II deficiency, it is possible that unrec-
ognized metabolic disorder may predispose patients to rhab-
domyolysis in influenza A (H1N1) infection leading to poor 
prognosis16. 
In the face of the worldwide H1N1 pandemic, physicians 
must recognize both the pulmonary and extrapulmonary 
complications of this novel infection. The study of Lorenzoni 
et al.12 demonstrates the importance of recognizing rhab-
domyolysis as a complication of H1N1 infection, possibly re-
lated to metabolic condition, and its potential association 
with life-threatening and prognosis.
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